Neurizon Therapeutics Limited

ASX:NUZ Stock Report

Market Cap: AU$94.9m

Neurizon Therapeutics Past Earnings Performance

Past criteria checks 0/6

Neurizon Therapeutics's earnings have been declining at an average annual rate of -37.6%, while the Pharmaceuticals industry saw earnings growing at 35.4% annually. Revenues have been declining at an average rate of 14.5% per year.

Key information

-37.6%

Earnings growth rate

-30.4%

EPS growth rate

Pharmaceuticals Industry Growth31.2%
Revenue growth rate-14.5%
Return on equity-87.0%
Net Margin-1,057.4%
Last Earnings Update30 Jun 2024

Recent past performance updates

Recent updates

Here's Why We're Not Too Worried About PharmAust's (ASX:PAA) Cash Burn Situation

Apr 09
Here's Why We're Not Too Worried About PharmAust's (ASX:PAA) Cash Burn Situation

Here's Why We're Not At All Concerned With PharmAust's (ASX:PAA) Cash Burn Situation

Mar 31
Here's Why We're Not At All Concerned With PharmAust's (ASX:PAA) Cash Burn Situation

Here's Why PharmAust Limited's (ASX:PAA) CEO Compensation Is The Least Of Shareholders Concerns

Nov 03
Here's Why PharmAust Limited's (ASX:PAA) CEO Compensation Is The Least Of Shareholders Concerns

Is PharmAust (ASX:PAA) In A Good Position To Deliver On Growth Plans?

May 30
Is PharmAust (ASX:PAA) In A Good Position To Deliver On Growth Plans?

This Is The Reason Why We Think PharmAust Limited's (ASX:PAA) CEO Might Be Underpaid

Oct 14
This Is The Reason Why We Think PharmAust Limited's (ASX:PAA) CEO Might Be Underpaid

What Does PharmAust's (ASX:PAA) CEO Pay Reveal?

Feb 14
What Does PharmAust's (ASX:PAA) CEO Pay Reveal?

Revenue & Expenses Breakdown

How Neurizon Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

ASX:NUZ Revenue, expenses and earnings (AUD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Jun 241-934
31 Mar 241-623
31 Dec 234-852
30 Sep 234-751
30 Jun 231-211
31 Mar 232-121
31 Dec 224-131
30 Sep 224-141
30 Jun 225-251
31 Mar 224-241
31 Dec 214-240
30 Sep 214-240
30 Jun 214-141
31 Mar 214-241
31 Dec 203-240
30 Sep 204-241
30 Jun 204-141
31 Mar 204-241
31 Dec 194-251
30 Sep 194-241
30 Jun 194-241
31 Mar 194-141
31 Dec 184-140
30 Sep 184-250
30 Jun 183-350
31 Mar 183-250
31 Dec 173-250
30 Sep 173-240
30 Jun 173-140
31 Mar 173-240
31 Dec 163-331
30 Sep 163-431
30 Jun 163-441
31 Mar 163-341
31 Dec 153-241
30 Sep 153-241
30 Jun 152-231
31 Mar 152-231
31 Dec 142-230
30 Sep 142-230
30 Jun 142-130
31 Dec 132-120

Quality Earnings: NUZ is currently unprofitable.

Growing Profit Margin: NUZ is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: NUZ is unprofitable, and losses have increased over the past 5 years at a rate of 37.6% per year.

Accelerating Growth: Unable to compare NUZ's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: NUZ is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (46.5%).


Return on Equity

High ROE: NUZ has a negative Return on Equity (-87.01%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies